In conclusion, in view of the fact that increasing the SUMOylation in skeletal muscle can enhance energy expenditure, inhibiting SENP2 expression could serve as a novel therapeutic approach to alleviate obesity and hyperlipidemia (Figure 5). The gene discussed is SENP2; the disease is obesity due to melanocortin 4 receptor deficiency.